氟伐他汀缓释片对高龄急性冠脉综合征患者近期疗效及安全性分析  

The Effect and Safety of Fluvastatin Sodium Extended Release Tablet for treatment of Very Elderly Patients with Acute Coronary Syndrome

作　　者：王婧如[1] 雷明明[1] 姚凤臣[1] 

机构地区：[1]中国医科大学附属第四医院

出　　处：《中西医结合心脑血管病杂志》2012年第3期263-265,共3页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

摘　　要：目的探讨氟伐他汀缓释片对高龄(年龄>80岁)急性冠脉综合征(acute coronary syndrome,ACS)患者的近期疗效及安全性。方法 82例高龄ACS患者,入院时随机分成两组。氟伐他汀组56例,给予氟伐他汀缓释片80mg,每晚一次口服。阿托伐他汀组26例,给予阿托伐他汀20mg,每晚一次口服。两组随访8周,观察血脂、肝功能、肾功能水平及缺血心脏事件(需住院治疗的心绞痛、心肌梗死、心源性死亡、心功能恶化)发生的影响。结果氟伐他汀缓释片组患者血脂水平总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)与治疗前相比有统计学意义(P<0.05),肝、肾功能与治疗前相比无统计学意义(P>0.05)。氟伐他汀缓释片组与阿托伐他汀组相比,在降低血脂水平及缺血性心脏事件发生率方面无统计学意义(P>0.05)。结论氟伐他汀缓释片可明显降低高龄ACS患者近期的血脂水平、改善预后;氟伐他汀缓释片在对肝肾功能的影响、近期降低血脂水平及缺血性心脏事件发生率方面,与阿托伐他汀相比具有同样的安全性及疗效。Objective To investigate the effect and safety of fluvatatin sodium extended release tablet for treatment of very elderly patients（pts）（more than 80 years old） with acute coronary syndrome（ACS）.Methods Eighty-two pts with ACS were randomly divided into two groups：Fluvastatin group（n=56） treated with fluvatatin sodium extended release tablet 80 mg/qn and atorvastatin group（n=26） treated with atorvastatin 20 mg/qn for 8 weeks.The total cholesterol（TC）,triglycerides（TG）,high-density lipoprotein cholestrol（HDL-C）,low-density lipoprotein cholesterol（LDL-C） and ischemic cardiac event rate were observed.Results The levels of TC and LDL-C in Fluvastatin group were decreased following the treatment（P0.05）,and liver and kidney function were not different compared with the atorvastatin group.There was no obviously difference in the ischemic cardiac event rate and lipid level.Conclusion Fluvatatin sodium extended release tablet（80 mg,once a day） could significantly decrease the blood lipid and improve the prognosis.Fluvatatin sodium extended release tablet was safety for very elderly pts with ACS.

关 键 词：氟伐他汀缓释片 阿托伐他汀 急性冠脉综合征 

分 类 号：R541.4[医药卫生—心血管疾病] R256.2[医药卫生—内科学]